A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks

  1. Reidar Kloster1,*,
  2. Knut Nestvold2,
  3. Steinar T Vilming3

Article first published online: 19 JAN 2002

DOI: 10.1046/j.1468-2982.1992.1203169.x

Issue

Cephalalgia

Cephalalgia

Volume 12, Issue 3, pages 169–171, June 1992

Additional Information

How to Cite

Kloster, R., Nestvold, K. and Vilming, S. T. (1992), A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia, 12: 169–171. doi: 10.1046/j.1468-2982.1992.1203169.x

Author Information

  1. 1

    Departments of Neurology of Vestfold Central Hospital Tønsberg, Norway;

  2. 2

    Akershus Central Hospital, Nordbyhagen, Norway;

  3. 3

    Ullevaal Hospital Oslo, Norway

*Reidar Kloster, Department of Neurology, Vestfold Central Hospital 3100 Tønsberg, Norway.

Publication History

  1. Issue published online: 19 JAN 2002
  2. Article first published online: 19 JAN 2002
  3. Received 2 March 1992, accepted 3 March 1992

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (22K)

Keywords:

  • lbuprofen;
  • migraine

The efficacy of ibuprofen, a non-steroidal anti-inflammatory drug, was assessed in the acute treatment of migraine. Twenty-five patients completed a double-blind placebo-controlled multicrossover trial. The initial dose of ibuprofen was 1200 mg. Six migraine attacks were randomly treated in each patient, three with ibuprofen and three with placebo. The results indicated a statistically significant reduction in the duration of the migraine attacks and also a statistically significant reduction in the severity of headache and nausea in the ibuprofen-treated attacks. The use of additional medication was significantly reduced in the ibuprofen-treated attacks (25.6% vs 57.5%), No serious side effects were reported. Ibuprofen is valuable in the treatment of acute migraine attacks.

Get PDF (22K)